IRWD
NASDAQ
US
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
$3,54
▼ $-0,36
(-9,23%)
Vol. 1.9M
8
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$548.2M
P/E
19,2
ROE
29,3%
Margine
8,4%
D/E
56,12
Beta
0,15
52W
$1–$5
Consenso Wall Street
10 analisti · Apr 20262
Acquisto forte
5
Compra
3
Mantieni
0
Vendi
0
Vendita forte
70,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
PRME
Prime Medicine Inc
$626.4M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24,6
$1.0B
PROK
Prokidney Corp
$673.9M
TECX
Tectonic Therapeutic Inc
$390.4M
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
CBIO
Crescent Biopharma Inc
$164.8M
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,01 | $-0,01 | $-0,02 |
| Set 2025 | $0,10 | $0,24 | +$0,14 |
| Giu 2025 | $0,04 | $0,14 | +$0,10 |
| Mar 2025 | $-0,05 | $-0,14 | $-0,09 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $90.5M | $41.1M | $85.2M | $122.1M | $47.7M |
| Utile netto | — | $2.3M | -$37.4M | $23.6M | $40.1M | -$2.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | 29.3% | 29.3% | 29.3% | 29.3% | 29.3% |
| P/E (TTM) | — | — | — | — | 19.94 | 19.20 |
| Net Margin | 27.7% | -2.6% | -2.6% | -2.6% | 8.4% | 8.4% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | — | 56.12 | 56.12 | 56.12 | 56.12 | 56.12 |
| Current Ratio | 0.82 | 0.82 | 0.82 | 0.82 | 1.13 | 1.13 |
Rapporti chiave
ROA (TTM)
8,1%
P/S (TTM)
1,62
P/B
2,9
EPS (TTM)
$0,14
CF/Share
$-5,48
Crescita ricavi 3A
-5,3%
52W High
$4,78
52W Low
$0,53
$0,53
Intervallo 52 settimane
$4,78
Salute finanziaria
Flusso di cassa libero
$74.6M
Debito netto
$382.3M
Liquidità
$215.5M
Debito totale
$597.8M
Aggiornato al Dic 31, 2025
Як IRWD виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка IRWD vs аналоги Biotechnology
P/E
19,2
▲
2%
sopra
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,6
▼
87%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
2,9
▲
18%
sopra
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість IRWD vs аналоги Biotechnology
ROE
29,3%
▲
144%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
8,4%
▲
103%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
100,0%
▲
27%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
8,1%
▲
117%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя IRWD vs аналоги Biotechnology
D/E ratio
56,1
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,1
▼
75%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,2
▼
84%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів IRWD
IRWD
Mediana peer
Industria
IRWD прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
IRWD vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
DENNER ALEXANDER J
Director · Mar 17
6730800 shs
DENNER ALEXANDER J
Director · Mar 13
4451 shs
MCCOURT THOMAS A
Chief Executive Officer · Mar 10
409836 shs
MARTINI GREGORY S.
Chief Financial Officer · Mar 10
136612 shs
GASKINS TAMMI L
Officer · Mar 10
136612 shs
SHETZLINE MICHAEL
Officer · Mar 10
136612 shs
SILVER RONALD
Officer · Mar 10
163934 shs
MINARDO JOHN
Officer · Mar 10
136612 shs
MARTINI GREGORY S.
Chief Financial Officer · Feb 24
21944 shs
GASKINS TAMMI L
Officer · Feb 24
21526 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 44,29%Armistice Capital, LLC
9,83%
$50.3M
Vanguard Group Inc
9,79%
$50.1M
Sarissa Capital Management,…
9,76%
$50.0M
Blackrock Inc.
7,84%
$40.1M
Bank of America Corporation
7,07%
$36.2M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora